中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBV相关肝细胞癌患者血清N-糖组图谱改变与肝组织糖基转移酶表达变化的关系

曹曦 孙艳玲 陈翠英 肖义炜 向宽辉 刘学恩 庄辉

引用本文:
Citation:

HBV相关肝细胞癌患者血清N-糖组图谱改变与肝组织糖基转移酶表达变化的关系

DOI: 10.3969/j.issn.1001-5256.2021.06.024
基金项目: 

“十三五”国家重大科技专项 (2018ZX10732401-003-015);

广西病毒性肝炎防治研究重点实验室开放课题基金项目 (GXCDCKL201901)

利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:曹曦完成实验和数据分析,撰写论文;孙艳玲、肖义炜、向宽辉参与收集标本和分析数据;陈翠英参与修改论文;刘学恩、庄辉负责课题设计,指导撰写文章并最后定稿。
详细信息
    作者简介:

    曹曦(1994—),男,主要从事病毒性肝炎相关研究

    通信作者:

    刘学恩,xueenliu@bjmu.edu.cn

    庄辉,zhuangbmu@126.com

  • 中图分类号: R735.7

Association between the alteration of serum N-glycan profile and the change of glycosyltransferase expression in liver tissue in patients with hepatitis B virus-related hepatocellular carcinoma

  • 摘要:   目的  本研究通过对HBV相关肝细胞癌(HCC)患者血清N-聚糖检测及肝癌组织与癌旁组织中糖基转移酶基因表达水平比较分析,探索HCC患者血清N-聚糖变化的可能机制。  方法  收集解放军总医院2018年—2019年HBV相关HCC手术患者(34例)的肝癌和癌旁组织及正常肝组织标本,同时采集血清标本。从34例HCC患者中随机选择8例HCC患者血清标本作为HCC试验组,20例健康成年人血清标本作为对照组。应用DSA-FACE法分析HCC试验组与对照组血清N-聚糖图谱。采用荧光定量PCR法检测34例HBV相关HCC患者癌组织和癌旁组织中8种糖基转移酶基因(FUT3、FUT4、FUT6、FUT7、FUT8、Gn-TⅢ、Gn-TⅣa和Gn-TⅤ)mRNA表达水平,并应用蛋白印迹法检测相应蛋白表达水平。计量资料两组间比较采用独立样本t检验。  结果  与对照相比,8例HCC患者血清中N-聚糖峰9 (peak9, NA3Fb)的丰度明显升高(t=-2.514, P<0.05)。糖基转移酶FUT8、Gn-TⅣa和Gn-TⅤ基因mRNA表达水平在癌组织和癌旁组织间有差异,其中癌组织中FUT8和Gn-TⅤ基因的mRNA与蛋白表达水平显著高于癌旁组织(mRNA: 1.50±0.34 vs 0.65±0.11, t=-2.354,P=0.022; 3.57±0.64 vs 1.33±0.16, t=-3.384, P=0.001)(蛋白:0.70±0.11 vs 0.083±0.017, t=9.555,P=0.001; 1.33±0.19 vs 0.60±0.15, t=5.097, P=0.007);癌组织中Gn-TⅣa基因的mRNA表达水平显著高于癌旁组织(mRNA: 2.90±0.47 vs 1.68±0.19, t=-2.403,P=0.019),蛋白表达水平与癌旁组织无显著差异(蛋白:0.52±0.24 vs0.24±0.11, t=1.833, P=0.141)。癌组织中这些糖基转移酶表达改变与血清中N-聚糖丰度变化一致。  结论  HBV相关HCC患者血清中一些N-聚糖水平变化可能与肝癌组织中糖基转移酶基因GnT-V、GnT-IVa和FUT8表达上调密切相关。

     

  • 图  1  HCC试验组与对照组血清N-聚糖图谱

    注:a,血清中12种N-聚糖丰度比较;b,12种N-聚糖结构。Peak1-Peak12图引自文献[4],Peak1: 二天线无半乳糖基核心ɑ-l, 6岩藻糖基化N聚糖(NGA2F);Peak2: 二天线无半乳糖基核心ɑ-l, 6岩藻糖基化平分型N聚糖(NGA2FB);Peak3/Peak4: 二天线核心ɑ-l, 6岩藻糖基化单支链半乳糖基N聚糖(NG1A2F);Peak5: 二天线N聚糖(NA2);Peak6: 二天线核心ɑ-l, 6岩藻糖基化N聚糖(NA2F);Peak7: 二天线平分型核心ɑ-l, 6岩藻糖基化N聚糖(NA2FB);Peak8: 三天线N聚糖(NA3);Peak9: 三天线支链ɑ-l, 3岩藻糖基化N聚糖(NA3Fb);Peak9’: 三天线核心ɑ-l, 6岩藻糖基化N聚糖(NA3Fc);Peak10: 三天线支链ɑ-l, 3岩藻糖基化与核心ɑ-l, 6岩藻糖基化N聚糖(NA3Fbc);Peak11: 四天线N聚糖(NA4);Peak12: 四天线支链ɑ-l, 3岩藻糖基化N聚糖(NA4 Fb)。

    图  2  癌组织与癌旁组织中8种糖基转移酶mRNA表达水平比较

    注:*,P<0.05,* *,P<0.01。

    图  3  癌组织与癌旁组织糖基转移酶FUT8、Gn-TⅣa和Gn-TⅤ的蛋白表达水平比较

    注:* *,P<0.01

    图  4  HBV相关HCC患者血清特异变化N-聚糖与8种糖基转移酶之间的关系

    表  1  荧光定量PCR检测糖基转移酶基因引物序列表

    基因 序列号 引物序列(5′→3′)
    FUT3 NM_001374740.1 F: CAA CAG AGA AAG CAG GCA
    R: AAG AAA CAC ACA GCC ACC[7]
    FUT4 XM_032167182.1 F: TCC TAC GGA GAG GCT CAG
    R: TCC TCG TAG TCC AAC ACG[7]
    FUT6 XM_011527879.3 F: CAT TTC TGC TGC CTC AGG
    R: GGG CAA GTC AGG CAA CTC[7]
    FUT7 NM_004479.4 F: CCA CGA TCA CCA TCC TTG
    R: AGG CTT CGG TTG GCA CTC[7]
    FUT8 XM_032180460.1 F: TCT AGC CGA GAA CTG TCC
    R: GCT GCT CTT CTA AAA CGC[7]
    Gn-TⅢ XM_019018480.2 F: CCG CCA CAA GGT GCT CTA T
    R: GAT CTC GTC CGC ATC GTC A[8]
    Gn-TⅣa XM_032178740.1 F: ACC AAG GGC ATA CGC TGG AG
    R: GTT CTT GGT TGC CGC TAT GGA[9]
    Gn-TV XM_032411636.1 F: GCT GCC CAA CTG TAG GAG AC
    R: GAA TCA AGG ACT CGG AGC AT[10]
    RPS11 XM_032159559.1 F: GCC GAG ACT ATC TGC ACT AC
    R: ATG TCC AGC CTC AGA ACT TC[11]
    下载: 导出CSV

    表  2  34例HBV-HCC患者临床特征

    临床特征 数值
    男性[例(%)] 29 (85.29)
    年龄(岁) 54.85±8.20
    HBV DNA(×106IU/ml) 2.35±7.15
    AFP(ng/ml) 556.82±1995.22
    ALT(U/L) 44.34±60.72
    AST(U/L) 40.71±44.25
    肿瘤直径(例)
      ≤5 cm 21
      5~10 cm 9
      ≥10 cm 4
    下载: 导出CSV
  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2] DRAKE RR. Glycosylation and cancer: Moving glycomics to the forefront[J]. Adv Cancer Res, 2015, 126: 1-10. DOI: 10.1016/bs.acr.2014.12.002.
    [3] HÄUSELMANN I, BORSIG L. Altered tumor-cell glycosylation promotes metastasis[J]. Front Oncol, 2014, 4: 28. DOI: 10.3389/fonc.2014.00028.
    [4] LIU XE, DESMYTER L, GAO CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J]. Hepatology, 2007, 46(5): 1426-1435. DOI: 10.1002/hep.21855.
    [5] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [6] CAO X, SHANG QH, CHI XL, et al. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus[J]. World J Gastroenterol, 2020, 26(10): 1067-1079. DOI: 10.3748/wjg.v26.i10.1067.
    [7] CHENG L, GAO S, SONG X, et al. Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs[J]. Oncotarget, 2016, 7(38): 61199-61214. DOI: 10.18632/oncotarget.11284.
    [8] CHEN C, DIAO D, GUO L, et al. All-trans-retinoic acid modulates ICAM-1 N-glycan composition by influencing GnT-Ⅲ levels and inhibits cell adhesion and trans-endothelial migration[J]. PLoS One, 2012, 7(12): e52975. DOI: 10.1371/journal.pone.0052975.
    [9] NIE H, LIU X, ZHANG Y, et al. Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation[J]. Sci Rep, 2015, 5: 16007. DOI: 10.1038/srep16007.
    [10] WANG G, LIU J, CAI Y, et al. Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis[J]. Oncotarget, 2017, 8(42): 71867-71880. DOI: 10.18632/oncotarget.18288.
    [11] WU X, DAO THI VL, LIU P, et al. Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems[J]. Gastroenterology, 2018, 154(3): 663-674. e7. DOI: 10.1053/j.gastro.2017.10.041.
    [12] KIZUKA Y, TANIGUCHI N. Enzymes for N-glycan branching and their genetic and nongenetic regulation in cancer[J]. Biomolecules, 2016, 6(2). DOI: 10.3390/biom6020025.
    [13] FANG M, ZHAO YP, ZHOU FG, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma[J]. Int J Cancer, 2010, 127(1): 148-159. DOI: 10.1002/ijc.25030.
    [14] CUI J, HUANG W, WU B, et al. N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis[J]. J Pathol, 2018, 245(1): 41-52. DOI: 10.1002/path.5054.
    [15] FAN J, WANG S, YU S, et al. N-acetylglucosaminyltransferase IVa regulates metastatic potential of mouse hepatocarcinoma cells through glycosylation of CD147[J]. Glycoconj J, 2012, 29(5-6): 323-334. DOI: 10.1007/s10719-012-9414-1.
    [16] ZHAO Y, NAKAGAWA T, ITOH S, et al. N-acetylglucosaminyltransferase Ⅲ antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration[J]. J Biol Chem, 2006, 281(43): 32122-32130. DOI: 10.1074/jbc.M607274200.
    [17] ZHAO Y, ITOH S, WANG X, et al. Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions[J]. J Biol Chem, 2006, 281(50): 38343-38350. DOI: 10.1074/jbc.M608764200.
    [18] DEBRUYNE EN, DELANGHE JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications[J]. Clin Chim Acta, 2008, 395(1-2): 19-26. DOI: 10.1016/j.cca.2008.05.010.
    [19] KEELEY TS, YANG S, LAU E. The diverse contributions of fucose linkages in cancer[J]. Cancers (Basel), 2019, 11(9). DOI: 10.3390/cancers11091241.
  • 加载中
图(4) / 表(2)
计量
  • 文章访问数:  464
  • HTML全文浏览量:  179
  • PDF下载量:  33
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-09
  • 录用日期:  2020-12-18
  • 出版日期:  2021-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回